Ibutamoren (Mk-677)

Ibutamoren (MK-677) is an orally active growth hormone secretagogue that raises growth hormone (GH) and insulin-like growth factor-1 (IGF-1) by mimicking ghrelin at the ghrelin receptor. Unlike injected GH, it promotes pulsatile GH release while keeping normal feedback mechanisms working, and it does not suppress the body's own testosterone. Originally developed to treat muscle wasting, osteoporosis, and growth hormone deficiency, it has since drawn attention for body composition, recovery, and sleep quality. Although grouped with peptides, it is taken orally rather than injected.

The evidence base is strong on paper, earning an A+ grade across 39 peer-reviewed studies (18 RCTs, 7 animal, 6 in vitro, and 4 reviews). But the outcome distribution is more nuanced than the grade suggests: of 39 classified findings, only 20 were supporting while 15 were mixed, 1 null, and 3 refuting. That high share of mixed and refuting results is an important caveat, and the 18 human RCTs paint a picture of a compound that reliably moves biomarkers but doesn't always deliver clinical benefits.

What the research shows is consistent on hormones and mechanism. Seven days of MK-677 raised 24-hour GH secretion by 50-89% and IGF-I by 52-79% without notably affecting cortisol, and it improved sleep quality and REM duration in both young and older adults. In obese men, eight weeks at 25 mg daily increased GH, added about 1.1 kg of fat-free mass, and raised metabolic rate without reducing fat mass. It fully reversed diet-induced negative nitrogen balance, pointing to a real anti-catabolic effect during calorie restriction, and it increased bone-turnover markers in elderly subjects. However, the benefits often stopped at biomarkers: in elderly hip-fracture patients an RCT found no meaningful improvement in functional recovery or hospital stay, and a 12-month Alzheimer's RCT showed no slowing of disease progression despite raising IGF-I. A case report combining LGD-4033 and MK-677 saw gains in lean and fat mass but harm to bone health, liver enzymes, lipids, and suppressed testosterone and FSH.

Who should be cautious: people with blood-sugar concerns, those not trying to gain weight, and athletes. Research and users report higher fasting glucose and possible insulin sensitivity problems, water retention is common, and the appetite spike that aids bulking is a liability otherwise. It is also a prohibited substance in sport and the military.

Community sentiment is split. Across 10 community reports, 50% were positive and 50% negative, with long duration, hunger signals, and increased appetite among reported effects and water retention the main complaint. Mention activity has fallen sharply year over year.

On dosing, most users and studies use 10-25 mg daily, with 25 mg the common research dose; many start at 10 mg to gauge tolerance, take it once at bedtime to match natural GH rhythms and sleep effects, and run 8-12 week cycles followed by breaks. Effectiveness is well documented for GH/IGF-1 elevation (40-89%) and muscle preservation during dieting, with solid sleep benefits, but direct fat loss is minimal, and body-composition changes mostly reflect added lean mass and water.

Availability is a red flag. MK-677 is not FDA-approved for human use, is classified as an unapproved drug, and is banned by WADA and the DoD. Despite that, it is widely sold online as a research chemical or, incorrectly, as a dietary supplement, raising real quality and safety concerns, and the FDA has issued warning letters over purity and labeling in these unregulated markets. Bottom line: it reliably moves hormones, but clinical payoff is inconsistent and the unregulated supply and metabolic side effects deserve serious caution.